Every year, more than 14,000 Americans sit in a doctor’s office and hear words that amount to a death sentence. Glioblastoma. Most people outside of medicine have never heard the name. But for those who receive the diagnosis, the math is brutal. Average survival sits between 12 and 18 months. Only one in 20 patients will still be alive after five years.

Surgery rarely gets all of it because the cancer weaves itself through brain tissue like roots through soil. Chemotherapy and radiation buy a few extra months at best, and the side effects can be devastating enough that some patients choose to skip treatment altogether. For decades, the medical community has thrown everything it has at glioblastoma and barely moved the needle.

But something unexpected has been building at the University of Virginia. A team of researchers, led by pathologist Hui Li, has been quietly chasing a lead that started in a completely different disease and ended up pointing toward a weakness hidden inside glioblastoma itself. And their latest findings, published in Science Translational Medicine, suggest they may have found a way to strike at that weakness with a simple compound that could one day be swallowed as a pill.

An Accidental Discovery in a Children’s Disease

Good science does not always follow a straight line. Li and his team were not searching for a glioblastoma treatment when they first caught the scent. Instead, they were studying rhabdomyosarcoma, a rare cancer that affects children. Childhood cancers tend to involve fewer mutations than adult cancers, making them easier to pick apart at the molecular level.

During that research, something odd showed up in a gene called AVIL. It was behaving in ways no one expected. Rather than set the finding aside, the team followed their curiosity and began looking at whether AVIL might be active in adult cancers, too. It was. And not just mildly active. In glioblastoma, AVIL was everywhere.

By 2020, the team had gathered enough evidence to publish their findings in Nature Communications. AVIL, they reported, was a bona fide oncogene, a cancer-causing gene responsible for triggering glioblastoma. When they described the discovery, Li did not mince words. “The novel oncogene we discovered promises to be an Achilles’ heel of glioblastoma,” he said, “with its specific targeting potentially an effective approach for the treatment of the disease.”

What AVIL Actually Does

In a healthy brain, AVIL barely registers. It produces a protein that helps cells keep their size and shape, a quiet housekeeping job. But in glioblastoma patients, the gene gets pushed into overdrive. Various factors can flip that switch, and once it flips, AVIL starts fueling cancer cells, helping them form and spread aggressively.

Lab data painted a stark picture. Every single glioblastoma sample tested showed AVIL overexpression. Glioblastoma stem cells, which are thought to drive the cancer’s resistance to treatment, carried even higher levels. Meanwhile, healthy brain tissue showed almost none.

When Li’s team silenced AVIL in lab mice, the results were dramatic. Glioblastoma cells were wiped out. Healthy cells were left untouched. Mice with the gene knocked out entirely showed no negative effects, suggesting the body can function perfectly well without it.

Here was a gene the cancer depended on completely, but the rest of the body barely needed. A target like that is rare in oncology, and researchers had reason to be excited. But a problem remained. Silencing a gene in a laboratory is one thing. Doing it safely inside a living human brain is something else entirely.

Hunting for a Molecule

Knowing AVIL was the engine behind glioblastoma was a major step, but it was not a treatment. Lab techniques used to silence genes in mice could not be safely applied to people. So the team set out to find a molecule, a chemical compound that could block AVIL’s activity in a way that might actually work as medicine.

Using a process called high-throughput screening, they tested enormous numbers of compounds at speed, searching for one that could bind to the AVIL protein and stop it from doing its job. After extensive testing, they found what they were looking for.

A small molecule emerged that latched onto the AVIL protein directly and prevented it from interacting with actin, the structural protein it normally binds to. When they analyzed the compound’s effects on gene expression, the profile closely matched what happened when AVIL was silenced through other methods. Two known downstream targets of AVIL, called FOXM1 and LIN28B, were both suppressed. In plain terms, the molecule did what the team hoped it would do. It shut AVIL down.

Results That Surprised Even the Researchers

Across five different mouse models of glioblastoma, including models resistant to temozolomide (the standard chemotherapy drug), the compound performed well. Tumors shrank. Mice survived longer. And perhaps most importantly, the molecule showed selectivity. It went after tumor cells while leaving healthy brain cells, including astrocytes and neural stem cells, alone. No harmful side effects appeared.

One of the biggest obstacles for any drug aimed at brain cancer is the blood-brain barrier, a biological shield that blocks most compounds from reaching the brain. Many promising drugs for neurological diseases have failed at precisely that point. But lab data confirmed that this molecule crosses the barrier readily. And it could potentially be taken by mouth, as a simple oral medication. No infusions, no injections.

“Glioblastoma is a devastating disease. Essentially no effective therapy exists,” Li said. “What’s novel here is that we’re targeting a protein that GBM cells uniquely depend on, and we can do it with a small molecule that has clear in vivo activity. To our knowledge, this pathway hasn’t been therapeutically exploited before.”

A Long Road Still Ahead

For all the excitement these findings carry, the compound is far from a finished drug. Before any glioblastoma patient can benefit, much more work is needed. Researchers must optimize the molecule for human biology, run extensive safety studies, and eventually navigate a full battery of clinical trials under FDA oversight.

Li has already taken steps to move the work forward. He founded a company called AVIL Therapeutics to develop AVIL inhibitors, and he and colleague Zhongqiu Xie have secured a patent related to the approach. UVA’s Paul and Diane Manning Institute of Biotechnology, along with a statewide clinical trials network, aims to speed up development and widen access to new treatments as they become available.

Funding from the National Institutes of Health and the Ben & Catherine Ivy Foundation supported the research, and the study appeared with a long list of co-authors whose collective work spanned years.

Still, Li is clear-eyed about the urgency. “GBM patients desperately need better options,” he said. “Standard therapy hasn’t fundamentally changed in decades, and survival remains dismal.”

What Happens Next Could Change Everything, or Nothing

Cancer research is full of promising lab results that never survive the jump to human patients. History teaches caution. But certain elements of this story set it apart from the usual pipeline of early-stage findings.

AVIL is barely present in healthy brains but is abundant in every glioblastoma sample tested. Blocking it kills cancer cells but leaves normal tissue unharmed. Knocking the gene out entirely in mice produces no ill effects. And now a small molecule exists that can do the blocking, cross the blood-brain barrier, and be taken orally.

None of that guarantees success in humans. But it adds up to a case that deserves serious attention and serious investment. For patients and families living under the shadow of a glioblastoma diagnosis, even cautious optimism is worth more than the nothing they have been offered for decades.

What a Hidden Gene Can Teach Us About Being Human

Sometimes the most important scientific findings begin not with a grand plan, but with curiosity pointed in an unexpected direction. Li’s team stumbled onto AVIL while studying a completely different cancer in children. Had they ignored that detour, the deadliest adult brain cancer might still lack even a hint of a treatable weakness.

For the thousands of people diagnosed with glioblastoma every year, and their families, that willingness to follow an unexpected lead may one day mean the difference between months and years. It is a reminder that life on Earth, however fragile, carries an astonishing capacity to resist its own destruction, if we are patient and relentless enough to find the right keys.

On a deeper level, the story of AVIL asks us to reconsider what it means to push against limits. A gene so small it barely registers in healthy brain tissue turns out to be the engine behind one of the most aggressive cancers known to medicine. And yet human beings, armed with nothing more than persistence and method, found it, named it, and began building a way to shut it down. In that effort lives something worth sitting with. Our sense of purpose may not be written in the stars or encoded in philosophy. It may live in the quiet, stubborn refusal to accept a death sentence as the final word.

Loading...